Date: 2014-10-30
Type of information: Collaboration agreement
Compound:
Company: Ariana Pharma (France) WIN Consortium
Therapeutic area: Cancer - Oncology
Type agreement: collaboration
Action mechanism:
Disease:
Details: * On October 29, 2014, Ariana Pharma, developer of innovative clinical data analysis and diagnostic solutions for the healthcare sector, announced it has joined the WIN Consortium as an official technology partner. The Consortium (Worldwide Innovative Networking in personalized cancer medicine) is a global collaboration of 40 leading organizations whose aim is to develop more effective cancer diagnostics and therapeutics, shorten clinical trial timelines and reduce the overall cost of cancer care.
The new WIN/Ariana partnership is expected to accelerate the translation of personalized medicine discoveries into widely available new standards of care for all cancer patients, leading to significantly improved clinical outcomes and a higher quality of life for cancer patients.
As a technology partner of the WIN Consortium, Ariana will have early access to the latest research, key opinion leaders, leading academic groups and personalized medicine clinical trials. Ariana uses OncoKEM®, a proprietary clinical decision support platform for personalized medicine, to transform big data into better therapeutic decisions for cancer patients. WIN is recognized for pioneering the evolution of next-generation clinical trials, which test personalized treatment selection strategies rather than single drugs. These strategies are driven by algorithms that match targeted therapies or combination therapies to individual tumor biological profiles based on diagnostic analysis of genomic data and other information. In 2013 the WIN Consortium chose Ariana Pharma to develop and globally commercialize groundbreaking decision support software in WIN’s WINTHER trial, the first state of the art clinical trial in personalized cancer medicine to help clinicians choose the best therapies for cancer patients. Ariana
retains exclusive global rights to commercialize software and algorithms validated by the WINTHER clinical trial through Ariana’s OncoKEM® platform.
Founded in 2010, WIN is an initiative from the Institut Gustave Roussy (France) and University of Texas MD Anderson cancer center (USA).WIN is a non-profit organization formed by 40 renowned members: Academic cancer centres (25 centres in 16 countries), companies (Blue Cross Blue Shield, Agilent Technologies, GE Healthcare, Oracle Health Services, Foundation Medicine, Millennium Takeda,AstraZeneca and Pfizer), non-profit organizations such as EORTC, Fondation ARC and Sage Bionetworks. WIN organizes an annual symposium in Paris dedicated to personalized medicine.
Financial terms:
Latest news:
